The direct and indirect roles of HBV in liver cancer: Prospective markers for HCC screening and potential therapeutic targets

Journal of Pathology

Volumn 235, Issue 2, 2015, Pages 355-367

  Ringelhan, Marc ^a,b,c   O'Connor, Tracy ^a   Protzer, Ulrike ^a   Heikenwalder, Mathias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Partner Site Munich   (Germany)

Author keywords

Chronic hepatitis B; Direct role of viral proteins; HBs antigen; HBV; HBx; HCC; Hepatocarcinogenesis; Liver cancer; X protein

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; VIRUS DNA; ANTIVIRUS AGENT; TUMOR MARKER; VIRUS PROTEIN;

ARTICLE; CANCER SCREENING; CELL DESTRUCTION; DNA REPLICATION; END STAGE LIVER DISEASE; GENE ACTIVATION; GENE TRANSLOCATION; GENOME; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONHUMAN; PLEIOTROPY; RISK FACTOR; RISK REDUCTION; VIRUS INHIBITION; ANIMAL; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER NEOPLASMS; PATHOGENICITY; PREDICTIVE VALUE; VIROLOGY; VIRULENCE; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD; VIRAL PROTEINS; VIRULENCE; VIRUS INTEGRATION;

EID: 84917706953     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4434     Document Type: Article

References (182)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273 e1261.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
3. Ringelhan M, Heikenwalder M, Protzer U. Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. Dig Dis 2013; 31: 138-151.
4. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
5. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-638.
6. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143.
7. Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81(suppl 1): 41-49.
8. World Health Organization. Hepatitis B. WHO Fact Sheet No. 204: http://www.who.int/mediacentre/factsheets/fs204/en/WHO 2012
9. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-55.
10. Lin CL, Kao JH. Risk stratifcation for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 10-17.
11. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
12. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005; 42: 760-777.
13. Shi Y, Wu YH, Wu W, et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012; 32: 231-240.
14. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049.
15. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60: 723-731.
16. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012; 12: 201-213.
17. Jilbert AR, Miller DS, Scougall CA, et al. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Vi ro l og y 1996; 226: 338-345.
18. Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Vi ro l 2009; 83: 9652-9662.
19. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specifc HBsAg sero-prevalence and endemicity. Vaccine 2012; 30: 2212-2219.
20. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 1-31.
21. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012; 12: 131.
22. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142: 773-781, e772.
23. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
24. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17: 1730-1733.
25. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-834.
26. Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat 2010; 17: 527-536.
27. Lucifora J, Xia Y, Reisinger F, et al. Specifc and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-1228.
28. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
29. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
30. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
31. Pollicino T, Cacciola I, Saffoti F, et al. Hepatitis B virus preS/S gene variants: pathobiology and clinical implications. J Hepatol 2014; 61: 408-417.
32. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol 2007; 13: 65-73.
33. Nassal M. Hepatitis B viruses: reverse transcription a different way. Vi r u s R e s 2008; 134: 235-249.
34. Protzer U, Schaller H. Immune escape by hepatitis B viruses. Vi r u s Genes 2000; 21: 27-37.
35. Chisari FV, Klopchin K, Moriyama T, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-1156.
36. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
37. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350.
38. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
39. Bauer T, Sprinzl M, Protzer U. Immune control of hepatitis B virus. Dig Dis 2011; 29: 423-433.
40. Billerbeck E, Bottler T, Thimme R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13: 4858-4864.
41. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813.
42. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778.
43. + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-3328.
44. + regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012; 56: 873-883.
45. Ringelhan M, Schmid RM, Geisler F. The NF-κB subunit RelA/p65 is dispensable for successful liver regeneration after partial hepatec-tomy in mice. PLoS One 2012; 7: e46469.
46. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
47. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
48. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
49. Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepato-carcinogenesis: lessons learned and future challenges. Cancer Lett 2011; 305: 123-143.
50. Weber A, Boger R, Vick B, et al. Hepatocyte-specifc deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010; 51: 1226-1236.
51. Pikarsky E, Porat RM, Stein I, et al. NF-KB functions as a tumour promoter in infammation-associated cancer. Nature 2004; 431: 461-466.
52. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
53. Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010; 30: 87-98.
54. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc 2006; 295: 65-73.
55. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
56. Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81(suppl 1): 41-49.
57. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
58. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
59. European Association for the Study of the L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
60. Liaw YF, Leung N, Kao JH, et al. Asian-Pacifc consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
61. Wong DK, Cheung AM, O'Rourke K, et al. Effect of a-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
62. Honer Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol 2014; 27: 105-112.
63. Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 2014; DOI: 10.1136/gutjnl-2013-306409 (in press).
64. Cornberg M, Protzer U, Petersen J, et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection-the German guideline]. Z Gastroenterol 2011; 49: 871-930.
65. Kawanaka M, Nishino K, Nakamura J, et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Cancer 2014; 3: 41-52.
66. Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-450.
67. Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648-1657.
68. Xia Y, Lucifora J, Reisinger F, et al. Virology. Response to Comment on 'Specifc and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA'. Science 2014; 344: 1237.
69. Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep 2012; 14: 37-46.
70. McMahon BJ. The infuence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3: 334-342.
71. + chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430.
72. Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012; 44: 765-769.
73. Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305: 1067-1073.
74. Kremsdorf D, Soussan P, Paterlini-Brechot P, et al. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823-3833.
75. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286: 52-59.
76. Brechot C, Gozuacik D, Murakami Y, et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-231.
77. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127: S56-61.
78. Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocel-lular carcinomas. Gut 2005; 54: 1162-1168.
79. Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Onco-gene 2003; 22: 3911-3916.
80. Jiang Z, Jhunjhunwala S, Liu J, et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012; 22: 593-601.
81. Jiang S, Yang Z, Li W, et al. Re-evaluation of the carcinogenic signifcance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One 2012; 7: e40363.
82. Heikenwalder M, Protzer U. LINE(1)s of evidence in HBV-driven liver cancer. Cell Host Microbe 2014; 15: 249-250.
83. Ding D, Lou X, Hua D, et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identifed by a next-generation sequencing-based approach. PLoS Genet 2012; 8: e1003065.
84. Li JW, Wan R, Yu CS, et al. ViralFusionSeq: accurately discover viral integration events and reconstruct fusion transcripts at single-base resolution. Bioinformatics 2013; 29: 649-651.
85. Lau CC, Sun T, Ching AK, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014; 25: 335-349.
86. Amaddeo G, Cao Q, Ladeiro Y, et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut 2014; DOI: 10.1136/gutjnl-2013-306228 (in press).
87. Hadziyannis S, Gerber MA, Vissoulis C, et al. Cytoplasmic hepatitis B antigen in 'ground-glass' hepatocytes of carriers. Arch Pathol 1973; 96: 327-330.
88. Su IJ, Wang HC, Wu HC, et al. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J Gastroenterol Hepatol 2008; 23: 1169-1174.
89. Wang HC, Wu HC, Chen CF, et al. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specifc pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003; 163: 2441-2449.
90. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-3407.
91. Barone M, Spano D, D'Apolito M, et al. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med 2006; 12: 115-123.
92. Na B, Huang Z, Wang Q, et al. Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. PLoS One 2011; 6: e26240.
93. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008; 13: 875-879.
94. ∗ mutant has a dominant negative secretion defect and alters the typical profle of viral rebound. Hepatology 2008; 48: 88-98.
95. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39(suppl 1): S124-132.
96. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003; 23: 5-20.
97. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529.
98. Moenner M, Pluquet O, Bouchecareilh M, et al. Integrated endo-plasmic reticulum stress responses in cancer. Cancer Res 2007; 67: 10631-10634.
99. Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell 2004; 15: 767-776.
100. Sosa V, Moline T, Somoza R, et al. Oxidative stress and cancer: an overview. Ageing Res Rev 2013; 12: 376-390.
101. Hagen TM, Huang S, Curnutte J, et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 1994; 91: 12808-12812.
102. Hung JH, Su IJ, Lei HY, et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-κBand pp38 mitogen-activated protein kinase. J Biol Chem 2004; 279: 46384-46392.
103. Block TM, Mehta AS, Fimmel CJ, et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-5107.
104. Hildt E, Munz B, Saher G, et al. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002; 21: 525-535.
105. Wang HC, Chang WT, Chang WW, et al. Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 2005; 41: 761-770.
106. Yang JC, Teng CF, Wu HC, et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009; 49: 1962-1971.
107. Kekule AS, Lauer U, Meyer M, et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactiva-tor. Nature 1990; 343: 457-461.
108. Liang X, Du J, Liu Y, et al. The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 2007; 12: 1827-1836.
109. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-1082.
110. Paterlini P, Poussin K, Kew M, et al. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-321.
111. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014; 20: 5951-5961.
112. Ou DP, Tao YM, Tang FQ, et al. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 2007; 120: 1208-1214.
113. Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320.
114. Yu DY, Moon HB, Son JK, et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999; 31: 123-132.
115. Terradillos O, Billet O, Renard CA, et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997; 14: 395-404.
116. Slagle BL, Lee TH, Medina D, et al. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996; 15: 261-269.
117. Hwang GY, Lin CY, Huang LM, et al. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. J Clin Microbiol 2003; 41: 5598-5603.
118. Misra KP, Mukherji A, Kumar V. The conserved amino-terminal region (amino acids 1-20) of the hepatitis B virus X protein shows a transrepression function. Vi r u s R e s 2004; 105: 157-165.
119. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011; 55: 996-1003.
120. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994; 68: 2026-2030.
121. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135.
122. Jin YM, Yun C, Park C, et al. Expression of hepatitis B virus X protein is closely correlated with the high periportal infammatory activity of liver diseases. J Viral Hepat 2001; 8: 322-330.
123. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007; 252: 157-170.
124. Feitelson MA. Mechanisms of HBx mediated liver cancer: multiple pathways and opportunities. In Lau JWY, ed. Hepatocellular Carcinoma-Basic Research, Lau JWY (ed.). InTech, 2012; 287-312: www.intechopen.com
125. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52: 594-604.
126. Madden CR, Slagle BL. Stimulation of cellular proliferation by hepatitis B virus X protein. Dis Markers 2001; 17: 153-157.
127. Bouchard M, Giannakopoulos S, Wang EH, et al. Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 2001; 75: 4247-4257.
128. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997; 94: 14707-14712.
129. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor-α. Proc Natl Acad Sci USA 1997; 94: 8744-8749.
130. Jung JK, Arora P, Pagano JS, et al. Expression of DNA methyltrans-ferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 2007; 67: 5771-5778.
131. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9: 714-723.
132. Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specifc DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91: 2230-2234.
133. Chan C, Wang Y, Chow PK, et al. Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. Mol Cell Biol 2013; 33: 485-497.
134. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994; 91: 10350-10354.
135. Tarn C, Lee S, Hu Y, et al. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001; 276: 34671-34680.
136. Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle 2005; 4: 1722-1724.
137. Park SH, Jung JK, Lim JS, et al. Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by downregulating levels of p16 and p21 via DNA methylation. J Gen Vi ro l 2011; 92: 1309-1317.
138. Lee S, Tarn C, Wang WH, et al. Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines. J Biol Chem 2002; 277: 8730-8740.
139. Yuan K, Lian Z, Sun B, et al. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One 2012; 7: e35331.
140. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099.
141. Wu HC, Tsai HW, Teng CF, et al. Ground-glass hepatocytes co-expressing hepatitis B virus X protein and surface antigens exhibit enhanced oncogenic effects and tumorigenesis. Hum Pathol 2014; 45: 1294-1301.
142. Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mito-chondrial membrane potential. J Virol 2008; 82: 6798-6811.
143. Yang B, Bouchard MJ. The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 2012; 86: 313-327.
144. Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001; 294: 2376-2378.
145. Srisuttee R, Koh SS, Park EH, et al. Up-regulation of Foxo4 mediated by hepatitis B virus X protein confers resistance to oxidative stress-induced cell death. Int J Mol Med 2011; 28: 255-260.
146. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012; 13: 89-102.
147. Yoo YG, Oh SH, Park ES, et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1α through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076-39084.
148. Liu LP, Hu BG, Ye C, et al. HBx mutants differentially affect the activation of hypoxia-inducible factor-1α in hepatocellular carcinoma. Br J Cancer 2014; 110: 1066-1073.
149. Yoo YG, Na TY, Seo HW, et al. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 2008; 27: 3405-3413.
150. Neo SY, Leow CK, Vega VB, et al. Identifcation of discriminators of hepatoma by gene expression profling using a minimal dataset approach. Hepatology 2004; 39: 944-953.
151. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
152. Berasain C, Ujue Latasa M, Urtasun R, et al. Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers (Basel) 2011; 3: 2444-2461.
153. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifes etiological infuences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760-764.
154. Liu J, Ahiekpor A, Li L, et al. Increased expression of ErbB-2 in liver is associated with hepatitis Bx antigen and shorter survival in patients with liver cancer. Int J Cancer 2009; 125: 1894-1901.
155. Ito Y, Takeda T, Sakon M, et al. Expression and clinical signifcance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84: 1377-1383.
156. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
157. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with β-catenin. Science 1993; 262: 1731-1734.
158. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-480.
159. Villanueva A, Llovet JM. Liver cancer in 2013: Mutational landscape of HCC-the end of the beginning. Nat Rev Clin Oncol 2014; 11: 73-74.
160. Zucman-Rossi J. Molecular classifcation of hepatocellular carcinoma. Dig Liver Dis 2010; 42(suppl 3): S235-241.
161. Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifes key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698.
162. Lee JO, Kwun HJ, Jung JK, et al. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltrans-ferase 1. Oncogene 2005; 24: 6617-6625.
163. Arzumanyan A, Friedman T, Kotei E, et al. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012; 31: 563-572.
164. Lara-Pezzi E, Roche S, Andrisani OM, et al. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene 2001; 20: 3323-3331.
165. Lara-Pezzi E, Serrador JM, Montoya MC, et al. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 2001; 33: 1270-1281.
166. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol 1997; 17: 6427-6436.
167. Li H, Chi CY, Lee S, et al. The mitogenic function of hepatitis B virus X protein resides within amino acids 51 to 140 and is modulated by N-and C-terminal regulatory regions. J Virol 2006; 80: 10554-10564.
168. Sze KM, Chu GK, Lee JM, et al. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances inva-siveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology 2013; 57: 131-139.
169. Lee JH, Han KH, Lee JM, et al. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol 2011; 18: 914-921.
170. Wang Q, Zhang T, Ye L, et al. Analysis of hepatitis B virus X gene (HBx) mutants in tissues of patients suffered from hepatocellular carcinoma in China. Cancer Epidemiol 2012; 36: 369-374.
171. Xie Y, Liu S, Zhao Y, et al. X protein mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma. Tumour Biol 2014; 35: 10325-10331.
172. Paterlini P, Poussin K, Kew M, et al. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-321.
173. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725-12734.
174. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10: 34-42.
175. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
176. Cheng AL, Kang YK, Chen Z, et al. Effcacy and safety of sorafenib in patients in the Asia-Pacifc region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
177. Sprinzl MF, Reisinger F, Puschnik A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57: 2358-2368.
178. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072-2079.
179. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
180. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
181. Nault JC, Zucman-Rossi J. Genetics of hepatocellular carcinoma: the next generation. J Hepatol 2014; 60: 224-226.
182. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classi-fcation of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.